JPMorgan Downgrades Replimune Due to Regulatory Uncertainty
Replimune’s cancer drug, RP1, hit a snag after an FDA meeting. Quick approval is now unlikely due to regulatory uncertainty, causing the stock to drop sharply (39% Thursday). The company is seeking a new way forward for the melanoma treatment.